Singapore Advanced Medicine collaborates with EnGeneIC
EnGeneIC is a clinical-stage biopharmaceutical company focused on its proprietary EDV® nanocell technology to deliver high dose chemotherapy drugs directly to cancer cells via packets tagged with specific antibody. The EDV™ nanocell forms the basis of a first-in-class antibody nanocell drug conjugate platform, delivering various therapeutic payloads with minimal toxicity. For cancer applications, this technology enables the delivery of potent chemotherapeutic agents, overcoming drug resistance, and killing tumor cells while simultaneously stimulating the patient’s immune system for a robust anti-tumor response. The company is currently in Phase IIa clinical trials in Australia and the USA, focusing on patients with challenging, low-survival cancers, including metastatic pancreatic cancer.
Early phase I/II trials have shown promising results in advanced pancreatic cancers that have progressed after multiple lines of treatments. The treatment is safe, and demonstrated longer survival than historical non-treated cohorts, with 50% of the patient group exhibiting at least stable tumour response.
Future line-ups
EngeneIC has now obtained FDA Fast Track. Upon completion of current studies in pancreatic cancers, further tailored treatments will be extended to other cancer types like Glioblastoma Multiforme, drug-resistant Osteosarcoma etc. These are cancers that are aggressive and traditionally chemo-resistant.
